Archetype Therapeutics, an AI-native drug discovery company, will present compelling in vivo proof-of-concept data for novel lung cancer therapeutics at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30. The invited oral presentation will showcase validation data on small molecules identified by the company's generative AI platform that demonstrate superior effectiveness in intercepting lung adenocarcinoma invasion compared to previously published compounds.
AI Platform Identifies Superior Anti-Invasion Molecules
The presentation will feature in vitro and in vivo validation data, including genetically engineered mouse model (GEMM) and xenograft studies, conducted in collaboration with Dr. Charles A. Powell's laboratory at the Icahn School of Medicine at Mount Sinai. The research demonstrates the ability of Archetype-identified molecules to prevent metastasis by targeting invasive lung cancer cells.
"Several months ago, we set out to validate molecular candidates discovered by the Archetype platform utilizing our published early-stage lung adenocarcinoma experimental protocols," said Dr. Powell. "We are excited to present the results at AACR, demonstrating that these candidates include small molecules that are effective and substantially outperform those previously identified using other approaches."
Strategic Partnerships for ADC Development
Archetype is leveraging its AI-discovered molecules through partnerships with contract research organizations Abzena and Alloy Therapeutics to design and develop antibody-drug conjugates (ADCs). These ADCs will incorporate clinical-stage and approved targeted therapy small molecules identified by the Archetype platform, representing a novel approach to treating early-stage lung adenocarcinoma.
"Archetype has demonstrated that we can advance from initiating an AI-driven research program to identifying molecules with compelling in vivo proof of concept data in just months and in a highly cost-efficient manner," said Tom Neyarapally, CEO and Co-Founder of Archetype Therapeutics. "We are excited about addressing unmet patient need in lung cancer by developing both ADCs with Abzena and Alloy Therapeutics utilizing targeted payloads, and developing standalone novel small molecules."
Generative Chemogenomics Technology
The Archetype platform utilizes generative chemogenomics to predict the biological changes that small molecules will induce without prior laboratory testing. The system combines this capability with patient clinicogenomic classifiers to predict clinical impact in genomically-defined patient cohorts, enabling the virtual screening of billions of potential drugs per day.
The disease-agnostic platform has been validated across multiple cancer types, including early-stage lung adenocarcinoma and metastatic castration-resistant prostate cancer, and has accurately predicted clinical trial outcomes and drug impacts in these diseases.
AACR Presentation Details
The research will be presented by Dr. Abhilasha Sinha, Assistant Professor at the Icahn School of Medicine at Mount Sinai, on Sunday, April 27, 2025, from 3:20-3:35 PM CDT in Room S103 at McCormick Place Convention Center. The abstract, titled "Massive scale phenotypic screening using Generative Chemogenomics repurposes safe drugs and discovers new drugs for intercepting early-stage lung adenocarcinoma progression," will be published in the online Proceedings of the AACR.
